2026-10-19T01:35:51Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/142682026-10-18T21:14:22Zopenairedrivercom_ebyu_10000col_ebyu_10001Synthesis and biological evaluation of phloroglucinol derivatives possessing α-glycosidase, acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase inhibitory activityBurmaoglu, SerdarYilmaz, Ali O.Taslimi, ParhamAlgul, OztekinKilic, DeryanurGulcin, Ilhamiacetylcholinesterasebutyrylcholinesterasecarbonic anhydrasephloroglucinol derivativesα-glycosidaseAnimalsCarbonic AnhydrasesDose-Response Relationship, DrugElectrophorusEnzyme InhibitorsGlycoside HydrolasesHorsesHumansMolecular Docking SimulationMolecular StructurePhloroglucinolStructure-Activity Relationship4 bromocinnamic acid4 bromocinnamic acid methyl ester4 bromocinnamyl alcohol4 bromocinnamyl bromide4 bromocinnamyl phloroglucinol4 chlorocinnamic acid methyl ester4 chlorocinnamyl alcohol4 chlorocinnamyl bromide4 chlorocinnamyl phloroglucinol4 fluorocinnamic acid4 fluorocinnamic acid methyl ester4 fluorocinnamyl alcohol4 fluorocinnamyl bromideA series of novel phloroglucinol derivatives were designed, synthesized, characterized spectroscopically and tested for their inhibitory activity against selected metabolic enzymes, including α-glycosidase, acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase I and II (hCA I and II). These compounds displayed nanomolar inhibition levels and showed Ki values of 1.14–3.92 nM against AChE, 0.24–1.64 nM against BChE, 6.73–51.10 nM against α-glycosidase, 1.80–5.10 nM against hCA I, and 1.14–5.45 nM against hCA II. © 2018 Deutsche Pharmazeutische GesellschaftWiley-VCH Verlag2018Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/14268https://doi.org/10.1002/ardp.2017003140365-6233enArchiv der Pharmazieinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14268